(Q38164816)

English

Efficacy, safety and clinical pharmacology of macitentan in comparison to other endothelin receptor antagonists in the treatment of pulmonary arterial hypertension

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

Efficacy, safety and clinical pharmacology of macitentan in comparison to other endothelin receptor antagonists in the treatment of pulmonary arterial hypertension (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

arterial hypertension

0 references

1 reference

ChEBI release 2020-05-28

author name string

Jasper Dingemanse

1

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

Patricia N Sidharta

2

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

Willis C Maddrey

3

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

Lewis J Rubin

4

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

Hani Mickail

5

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

language of work or name

0 references

publication date

22 November 2013

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

Expert Opinion on Drug Safety

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

13

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

391-405

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

Guidelines for the diagnosis and treatment of pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.859674

21 January 2018

Updated clinical classification of pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.859674

21 January 2018

Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.859674

21 January 2018

Ambrisentan therapy for pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.859674

21 January 2018

Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2.

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.859674

21 January 2018

Sildenafil citrate therapy for pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.859674

21 January 2018

Tadalafil therapy for pulmonary arterial hypertension.

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.859674

21 January 2018

Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.859674

21 January 2018

A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.859674

21 January 2018

Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.859674

21 January 2018

Inhaled iloprost for severe pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.859674

21 January 2018

Sitaxsentan therapy for pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.859674

21 January 2018

Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the In

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.859674

21 January 2018

ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American Coll

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.859674

21 January 2018

Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing.

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.859674

21 January 2018

Heart rate responses during the 6-minute walk test in pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.859674

21 January 2018

Bosentan therapy in patients with pulmonary arterial hypertension: the relationship between improvements in 6 minute walk distance and quality of life

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.859674

21 January 2018

Pulmonary arterial hypertension in France: results from a national registry

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.859674

21 January 2018

Systematic review of trials using vasodilators in pulmonary arterial hypertension: why a new approach is needed

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.859674

21 January 2018

Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension.

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.859674

21 January 2018

Baseline and follow-up 6-min walk distance and brain natriuretic peptide predict 2-year mortality in pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.859674

21 January 2018

The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension.

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.859674

21 January 2018

Validation of 6-minute walk distance as a surrogate end point in pulmonary arterial hypertension trials

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.859674

21 January 2018

The 6-minute walk test in pulmonary arterial hypertension: how far is enough?

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.859674

21 January 2018

End-points and clinical trial design in pulmonary arterial hypertension: have we made progress?

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.859674

21 January 2018

Clinical worsening in trials of pulmonary arterial hypertension: results and implications.

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.859674

21 January 2018

End points and clinical trial design in pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.859674

21 January 2018

The discovery of N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-propylsulfamide (Macitentan), an orally active, potent dual endothelin receptor antagonist

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.859674

21 January 2018

Role of endothelin in the increased vascular tone of patients with essential hypertension

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.859674

21 January 2018

Mechanisms of ET-1-induced endothelial dysfunction

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.859674

21 January 2018

Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.859674

21 January 2018

At the heart of tissue: endothelin system and end-organ damage

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.859674

21 January 2018

Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.859674

21 January 2018

Macitentan and morbidity and mortality in pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.859674

21 January 2018

Role of endothelin receptor antagonists in the treatment of pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.859674

21 January 2018

Endothelin receptor antagonists for the treatment of pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.859674

21 January 2018

The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.859674

21 January 2018

Evaluation of the endothelin receptor antagonists ambrisentan, darusentan, bosentan, and sitaxsentan as substrates and inhibitors of hepatobiliary transporters in sandwich-cultured human hepatocytes

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.859674

21 January 2018

Cardiovascular diseases and the liver

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.859674

21 January 2018

Cardiac hepatopathy: clinical, hemodynamic, and histologic characteristics and correlations

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.859674

21 January 2018

Fulminant hepatic necrosis resulting from heart failure

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.859674

21 January 2018

Bilirubin as a prognostic marker in patients with pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.859674

21 January 2018

Results of European post-marketing surveillance of bosentan in pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.859674

21 January 2018

Hepatic manifestations of autoimmune rheumatic diseases

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.859674

21 January 2018

A case of cholestatic autoimmune hepatitis and acute liver failure: an unusual hepatic manifestation of mixed connective tissue disease and Sjögren's syndrome

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.859674

21 January 2018

Mixed connective tissue disease associated with autoimmune hepatitis and thyroiditis

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.859674

21 January 2018

Connective tissue diseases and the liver

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.859674

21 January 2018

Autoimmune Hepatitis

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.859674

21 January 2018

Macitentan: entry-into-humans study with a new endothelin receptor antagonist

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.859674

21 January 2018

Pharmacokinetics of macitentan in caucasian and Japanese subjects: the influence of ethnicity and sex.

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.859674

21 January 2018

Clinical pharmacology of bosentan, a dual endothelin receptor antagonist

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.859674

21 January 2018

Absorption, distribution, metabolism, and excretion of macitentan, a dual endothelin receptor antagonist, in humans

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.859674

21 January 2018

Effect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonist

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.859674

21 January 2018

Interaction profile of macitentan, a new non-selective endothelin-1 receptor antagonist, in vitro

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.859674

21 January 2018

Effect of the urotensin-II receptor antagonist palosuran on secretion of and sensitivity to insulin in patients with Type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.859674

21 January 2018

The pharmacokinetics and pharmacodynamics of warfarin in combination with ambrisentan in healthy volunteers

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.859674

21 January 2018

Potential for pharmacokinetic interactions between ambrisentan and cyclosporine

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.859674

21 January 2018

Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.859674

21 January 2018

Updated evidence-based treatment algorithm in pulmonary arterial hypertension.

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.859674

21 January 2018

The use of combination therapy in pulmonary arterial hypertension: new developments.

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.859674

21 January 2018

Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.859674

21 January 2018

Acute hemodynamic effects of single-dose sildenafil when added to established bosentan therapy in patients with pulmonary arterial hypertension: results of the COMPASS-1 study

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.859674

21 January 2018

Pharmacokinetics and safety of ambrisentan in combination with sildenafil in healthy volunteers

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.859674

21 January 2018

Investigation of the effects of ketoconazole on the pharmacokinetics of macitentan, a novel dual endothelin receptor antagonist, in healthy subjects

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.859674

21 January 2018

Single- and multiple-dose pharmacokinetics of bosentan and its interaction with ketoconazole

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.859674

21 January 2018

Effect of ketoconazole on the pharmacokinetic profile of ambrisentan.

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.859674

21 January 2018

Clinical pharmacokinetics and drug-drug interactions of endothelin receptor antagonists in pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.859674

21 January 2018

Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.859674

21 January 2018

Riociguat for the treatment of pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.859674

21 January 2018

Pathways in pulmonary arterial hypertension: the future is here.

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.859674

21 January 2018

Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.859674

21 January 2018

Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.859674

21 January 2018

Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2.

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.859674

21 January 2018

Do Changes of 6-Minute Walk Distance Predict Clinical Events in Patients With Pulmonary Arterial Hypertension?

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.859674

21 January 2018

Identifiers

10.1517/14740338.2014.859674

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38164816&oldid=1744266642"